Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
C-type natriuretic peptide moderates titin-based cardiomyocyte stiffness
Konstanze Michel, … , Nazha Hamdani, Michaela Kuhn
Konstanze Michel, … , Nazha Hamdani, Michaela Kuhn
Published October 15, 2020
Citation Information: JCI Insight. 2020;5(22):e139910. https://doi.org/10.1172/jci.insight.139910.
View: Text | PDF
Research Article Cardiology

C-type natriuretic peptide moderates titin-based cardiomyocyte stiffness

  • Text
  • PDF
Abstract

Heart failure is often accompanied by titin-dependent myocardial stiffness. Phosphorylation of titin by cGMP-dependent protein kinase I (PKGI) increases cardiomyocyte distensibility. The upstream pathways stimulating PKGI-mediated titin phosphorylation are unclear. We studied whether C-type natriuretic peptide (CNP), via its guanylyl cyclase-B (GC-B) receptor and cGMP/PKGI signaling, modulates titin-based ventricular compliance. To dissect GC-B–mediated effects of endogenous CNP in cardiomyocytes, we generated mice with cardiomyocyte-restricted GC-B deletion (CM GC-B–KO mice). The impact on heart morphology and function, myocyte passive tension, and titin isoform expression and phosphorylation was studied at baseline and after increased afterload induced by transverse aortic constriction (TAC). Pressure overload increased left ventricular endothelial CNP expression, with an early peak after 3 days. Concomitantly, titin phosphorylation at Ser4080, the site phosphorylated by PKGI, was augmented. Notably, in CM GC-B–KO mice this titin response was abolished. TAC-induced hypertrophy and fibrosis were not different between genotypes. However, the KO mice presented mild systolic and diastolic dysfunction together with myocyte stiffness, which were not observed in control littermates. In vitro, recombinant PKGI rescued reduced titin-Ser4080 phosphorylation and reverted passive stiffness of GC-B–deficient cardiomyocytes. CNP-induced activation of GC-B/cGMP/PKGI signaling in cardiomyocytes provides a protecting regulatory circuit preventing titin-based myocyte stiffening during early phases of pressure overload.

Authors

Konstanze Michel, Melissa Herwig, Franziska Werner, Katarina Špiranec Spes, Marco Abeßer, Kai Schuh, Swati Dabral, Andreas Mügge, Hideo A. Baba, Boris V. Skryabin, Nazha Hamdani, Michaela Kuhn

×

Figure 8

Addition of recombinant PKGI enhanced total Ser/Thr- and Ser4080-titin phosphorylation in skinned CMs prepared from CM GC-B–KO mice after TAC.

Options: View larger image (or click on image) Download as PowerPoint
Addition of recombinant PKGI enhanced total Ser/Thr- and Ser4080-titin p...
LV CMs were prepared from CM GC-B–KO mice after 3 days (A) or 14 days (B) of TAC. Western blot analyses were performed using an antibody against total Ser/Thr-phosphorylated titin (left panel) and a phospho-site–specific antibody recognizing titin phosphorylated at Ser4080 (the PKGI-specific site) (right panel). The levels of phosphorylated titin were normalized to total titin (PVDF) and calculated as percentage (%) from the mean value of the untreated (-PKGI) sample group. Data are shown as means ± SEM. n = 8/group, *P < 0.05 versus untreated samples (-PKGI) (2-tailed Student’s t test).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts